-
Listing
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesRead moreTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingRead moreEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeRead moreEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Read moreThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Read moreShaping capital markets for future generations
Listing of biotech company arGEN-X on EnterNext in Brussels
10/07/2014
As of 10 July 2014 arGEN-X is listed on the Brussels markets. To celebrate this event, Tim Van Hauwermeiren, CEO of arGEN-X, opened the markets with a Bell Ceremony. Hans de Haard, co-founder of arGEN-X, had the honor to write the first opening price on the blackboard. The reference price was fixed at 8.50 euro.
arGEN-X specializes in researching and developing human monoclonal antibodies for the treatment of oncological, autoimmune and inflammatory diseases.
At the end of 2013, the company had a portfolio of 2 products in phase I of clinical development and 3 products in preclinical development phase.
The ticker code of arGEN-X is : ARGX.
If you would like to find out more : www.argen-x.com